Diagnostic agent, method for detecting a carcinoma, and means for the treatment thereof
OwnerJürgen Doldererinventor
Life of this patent
Estimating the term…
Abstract
A diagnostic agent and a method for detecting a carcinoma are described, where at least one HERG potassium channel is detected in a tissue biopsy of the human colon or rectum. In addition, the use of the antiarrhythmic agent E-4031 for treatment of colorectal carcinoma is described.
Claims5
A method of diagnosing a colorectal carcinoma having at least one HERG potassium channel in a patient suspected of suffering from colorectal carcinoma, which comprises the steps of:
- (a) obtaining from the patient a biopsy of colorectal tissue, lymph nodes or a sample of body fluid or stool, wherein the colorectal tissue, lymph nodes, body fluid, or stool are free of HERG potassium channels in a patient free of colorectal cancer;
- (b) detecting as a selective tumor marker any presence of at least one HERG potassium channel in the biopsy of colorectal tissue, lymph nodes, or in the body fluid or stool;
- and
- (c) relating detection of any presence of HERG potassium channel in the biopsy or sample to the diagnosis in the patient of colorectal carcinoma having at least one HERG potassium channel.
A method of diagnosing a colorectal carcinoma having at least one HERG potassium channel in a patient suspected of suffering from colorectal carcinoma, and in the event that colorectal carcinoma having at least one HERG potassium channel is diagnosed in the patient, treating the patient for colorectal carcinoma, which comprises the steps of:
- (a) obtaining from the patient a biopsy of colorectal tissue, lymph nodes or a sample of body fluid or stool, wherein the colorectal tissue, lymph nodes, body fluid, or stool are free of HERG potassium channels in a patient free of colorectal cancer;
- (b) detecting as a selective tumor marker any presence of at least one HERG potassium channel in the biopsy of colorectal tissue, lymph nodes, or in the body fluid or stool;
- (c) relating detection of any presence of HERG potassium channel in the biopsy or sample to the diagnosis in the patient of colorectal carcinoma having at least one HERG potassium channel, and in the event of detecting the presence of HERG potassium channel in the biopsy or sample;
- (d) administering to said patient, a therapeutically effective amount of 4-[1-{2-(6-methyl-2-pyridinyl)ethyl-4-piperidinyl}carbonyl]methane-sulfoanilide 2HCl sufficient to treat the colorectal carcinoma having at least one HERG potassium channel.
Dependencies are inferred from the claim text.